2-氨基-7-溴喹唑啉-4-醇 | 885277-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-氨基-7-溴喹唑啉-4-醇
• 英文名称: 2-amino-7-bromoquinazolin-4(3H)-one
• 英文别名: 2-Amino-7-bromo-3H-quinazolin-4-one；2-amino-7-bromo-3H-quinazolin-4-one
• CAS: 885277-56-5
• 化学式: C₈H₆BrN₃O
• 分子量: 240.059
• InChiKey: ZEZJZZPBSKSEOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-氨基-7-溴喹唑啉-4-醇 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 17.0h， 生成 N-(7-bromo-4-(1H-1,2,4-triazol-1-yl)quinazolin-2-yl)acetamide
  参考文献：
  名称：

  Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics

  摘要：

  The histamine H-4 receptor is a G protein-coupled receptor that has attracted much interest for its role in inflammatory and immunomodulatory functions. In our search for new H4R ligands, a low affinity isoquinoline fragment was optimized to 7-(furan-2-yl)-4-(piperazin-1-yl)quinazolin-2-amine (VUF11489), as a new H4R antagonist. Analysis of its binding kinetics at the human H4R showed this compound to have a very different dissociative half-life in comparison with reference antagonist JNJ7777120. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.104
• 作为产物：
  描述：

  氰胺 、 2-氨基-4-溴苯甲酸甲酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以85%的产率得到2-氨基-7-溴喹唑啉-4-醇
  参考文献：
  名称：

  WO2020150115A5

  摘要：

  公开号：

  WO2020150115A5

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS HISTAMINE H4-RECEPT0R INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE LA QUINAZOLINE SERVANT D'INHIBITEURS DU RÉCEPTEUR H4 DE L'HISTAMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

  公开号：WO2010146173A1

  公开（公告）日：2010-12-23

  Compounds that modulate the histamine H4 receptor, and which may be useful for treating or preventing disorders and conditions mediated by the histamine H4 receptor, e.g. inflammation, are of Formula (I):

  调节组胺H4受体的化合物，可能用于治疗或预防由组胺H4受体介导的疾病和症状，例如炎症，其化学式为(I)：
• [EN] COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES<br/>[FR] ASSOCIATION DE VACCINS CONTRE LE VIRUS DE L'HÉPATITE B (VHB) ET DE DÉRIVÉS DE QUINAZOLINE
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2020255039A1

  公开（公告）日：2020-12-24

  Therapeutic combinations of hepatitis B virus (HBV) vaccines and quinazoline derivatives are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

  描述了乙型肝炎病毒（HBV）疫苗和喹唑啉衍生物的治疗组合。还描述了利用所披露的治疗组合诱导免疫应答对抗HBV或治疗HBV引起的疾病的方法，特别是在患有慢性HBV感染的个体中。该发明提供了用于诱导对乙型肝炎病毒（HBV）感染的免疫应答的治疗组合或组成物和方法。
• [EN] 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF<br/>[FR] DÉRIVÉS DE 2,4-DIAMINOQUINAZOLINE ET LEURS UTILISATIONS MÉDICALES
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2019166532A1

  公开（公告）日：2019-09-06

  This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), R1 is a C3-8alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C1-3 alkyl, or C1-3 alkoxy, the carbon of R1 bonded to the amine in the 4-position of the quinazoline is in (R)-configuration, R2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, R3 is hydrogen or deuterium, R4 is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C4-7 heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C4-7 heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, R5 is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R2, R3, R4 and R5 is not hydrogen.

  该申请涉及公式(I)的喹唑啉衍生物，包括公式(I)化合物的药物组合物，以及公式(I)化合物在治疗或预防病毒感染、病毒诱导的疾病、癌症或过敏症中的用途。在公式(I)中，R1是C3-8烷基，可选择地由一个或多个取代基独立选择自氟、羟基、氨基、腈基、酯基、酰胺基、C1-3烷基或C1-3烷氧基取代，与喹唑啉的4位胺键合的R1的碳处于(R)-构型，R2是氢、氘、氟、氯、甲基、甲氧基、环丙基、三氟甲基或羧酰胺基，其中每个甲基、甲氧基和环丙基可选择地由一个或多个取代基独立选择自氟和腈基，R3是氢或氘，R4是氢、氘、氟、甲基、羧酸酯、羧酰胺、腈基、环丙基、C4-7杂环或5-成员杂环芳基，其中每个甲基、环丙基、C4-7杂环和5-成员杂环芳基可选择地由一个或多个取代基独立选择自氟、羟基或甲基，R5是氢、氘、氟、氯、甲基或甲氧基，但要求R2、R3、R4和R5中至少有一个不是氢。
• Quinazoline protein tyrosine phosphatase inhibitors
  申请人：Berthel Joseph Steven

  公开号：US20060211715A1

  公开（公告）日：2006-09-21

  The present invention comprises aminoquinazoline compounds of the general formula I: wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

  本发明涵盖通式I的氨基喹唑啉化合物：其中X是未取代或取代的苯基，或未取代或取代的5或6元杂环芳香族环。本发明的化合物是PTP1B的有效抑制剂。因此，本发明还包括治疗或预防PTP-1B介导的疾病，包括糖尿病、肥胖症和糖尿病相关疾病的药物组合物和方法。
• Quinazoline Protein Tyrosine Phosphatase Inhibitors
  申请人：Berthel Steven Joseph

  公开号：US20090105477A1

  公开（公告）日：2009-04-23

  The present invention comprises aminoquinazoline compounds of the general formula I: wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

  本发明涉及一种一般式I的氨基喹唑啉化合物:其中X是未取代或取代的苯基，或未取代或取代的5或6元杂环芳香环。本发明的化合物是PTP1B的有效抑制剂。因此，本发明还包括制备药物组合物和治疗或预防PTP-1B介导的疾病，包括糖尿病，肥胖症和糖尿病相关疾病的方法。